-
ALSO READ
Northeastern states experience higher burden of cancers in men, women: ICMR
Strong product pipeline, valuations keep street positive on Aurobindo
Culture is binding thread across different regions of India: Amit Shah
A new study finds importance of malaria drug in treating neck cancers
Cells with cancer-related mutations overtake human tissue with age: Study
-
Drug major Aurobindo Pharma on Wednesday said its wholly-owned subsidiary has received approval from the US health regulator to market anti-cancer medication Bortezomib for injection.
Eugia Pharma Specialties has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market the product, a generic equivalent of Takeda Pharmaceuticals' Velcade for injection, the Hyderabad-based company said in a statement.
The product, which is indicated for the treatment of multiple myeloma (cancer of plasma cells) and mantle cell lymphoma (cancer of lymph nodes), is being launched immediately, it added.
According to IQVIA, the approved product has a market size of USD 1,172 million for the twelve months ending March 2022.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
First Published: Wed, May 04 2022. 14:01 IST
RECOMMENDED FOR YOU